1. Generics Bulletin
  2. >>Business

Apotex Adds Branded Division With Searchlight Acquisition

Builds On Recent Deal With Harrow To Accelerate Growth In Specialty Segment

 
• By Dave Wallace

Apotex has taken a major step to bolster its innovative interests with the acquisition of fellow Canadian firm and specialty branded player Searchlight Pharma.

Lighthouse silhouette with searchlight across bay
Apotex has sought out a branded platform in Searchlight • Source: Shutterstock

Apotex has struck a deal to acquire fellow private Canadian company and branded player Searchlight Pharma, in a move that the generics and biosimilars specialist says will “create a Canadian health champion spanning generic, biosimilar and branded pharmaceuticals.”

Financial details of the transaction were not disclosed, although a report in Canada’s Globe and Mail valued Searchlight at over...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Accord Takes On Ustekinumab Rivals In US With Steepest Discount Yet

 
• By Dave Wallace

Boasting the “lowest WAC price among branded biosimilars to Stelara”, Accord BioPharma has launched its Imuldosa version of ustekinumab in the US at a 92% discount to the blockbuster immunology brand.

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By Vibha Ravi

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

Formycon’s Search For Keytruda Biosimilar Partner Is Key To Deliver FY2025 Guidance

 
• By Urtė Fultinavičiūtė

With H1 revenues not even hitting double-digits, Formycon is bidding on partnerships and royalties to generate at least €46m over the next half-year to reach its revenue goal.